Streck Adds Ortho VITROS Instrument to A1c-Cellular Assay
16 Mar 2016Streck’s A1c-Cellular® is now assayed for the Ortho-Clinical Diagnostics VITROS® 4600.
A1c-Cellular is the first HbA1c control on the market with intact red blood cells. A1c-Cellular tests the accuracy and linear reportable range of the HbA1c parameter. It tests the entire HbA1c procedure, including the lysing of the red blood cell – a step omitted with other controls.
A1c-Cellular is also assayed for Abbott ARCHITECT® c Systems/ARCHITECT® i/Integrated c i Systems, ARKRAY Menarini ADAMS™ A1c HA-8160, Beckman Coulter® UniCel® DxC 600/800, Bio-Rad® D-10™/Variant II™/Variant II™ Turbo, Siemens Dimension Series, VITROS® 5,1 FS/5600, Roche cobas INTEGRA®/6000/c 311 and Tosoh G7/G8.
A1c-Cellular is available in plastic cap-pierceable vials which allow autosampling for HbA1c analyzers with such capabilities. The product is a ready-to-use liquid control appropriate for immunoassay and ionic exchange HPLC methodologies, with 180-day closed-vial stability and 30-day open-vial stability.
Streck also offers A1c-Cellular® Linearity, the only commercially available HbA1c linearity/calibration verification material with intact red blood cells. A1c-Cellular Linearity is available in a 5-level set with plastic cap-pierceable vials which allow autosampling for HbA1c analyzers with such capabilities. It has 105-day closed-vial stability and 7-day open-vial stability.
